CAR 2.0: The Next Generation of Synthetic Receptor-Based Cellular Therapy for Cancer

Elad Jacoby; Terry J. Fry

doi:10.1016/B978-0-323-66181-2.00013-5

CAR 2.0: The Next Generation of Synthetic Receptor-Based Cellular Therapy for Cancer

Elad Jacoby, Terry J. Fry

Pediatrics

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The successes of chimeric antigen receptor (CAR) T-cells has revealed many challenges resulting in an explosion of T-cell engineering solutions, most not yet tested in patients. The synthetic nature of the CAR design and almost limitless options that advanced genetic engineering offers pave the way to the next-generation CAR: one that targets multiple antigens with specificity to the tumor, that overcomes immunosuppressive environments in solid tumors or the central nervous system, that has controllable persistence and activation, and that is “off the shelf.” In this chapter, we will cover these challenges and their underlying mechanisms and discuss preclinical and clinical results aimed to tackle them.

Original language	English
Title of host publication	Chimeric Antigen Receptor T-Cell Therapies for Cancer
Subtitle of host publication	A Practical Guide
Publisher	Elsevier
Pages	199-208
Number of pages	10
ISBN (Electronic)	9780323661812
ISBN (Print)	9780323755979
DOIs	https://doi.org/10.1016/B978-0-323-66181-2.00013-5
State	Published - 1 Jan 2020

Keywords

Adoptive T-cell therapy
Chimeric antigen receptor
Genetically modified T-cells
T-cell engineering

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-323-66181-2.00013-5

Cite this

@inbook{a9b42f37934046e8aad3f5747b681cef,

title = "CAR 2.0: The Next Generation of Synthetic Receptor-Based Cellular Therapy for Cancer",

abstract = "The successes of chimeric antigen receptor (CAR) T-cells has revealed many challenges resulting in an explosion of T-cell engineering solutions, most not yet tested in patients. The synthetic nature of the CAR design and almost limitless options that advanced genetic engineering offers pave the way to the next-generation CAR: one that targets multiple antigens with specificity to the tumor, that overcomes immunosuppressive environments in solid tumors or the central nervous system, that has controllable persistence and activation, and that is “off the shelf.” In this chapter, we will cover these challenges and their underlying mechanisms and discuss preclinical and clinical results aimed to tackle them.",

keywords = "Adoptive T-cell therapy, Chimeric antigen receptor, Genetically modified T-cells, T-cell engineering",

author = "Elad Jacoby and Fry, {Terry J.}",

year = "2020",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-66181-2.00013-5",

language = "אנגלית",

isbn = "9780323755979",

pages = "199--208",

booktitle = "Chimeric Antigen Receptor T-Cell Therapies for Cancer",

publisher = "Elsevier",

address = "הולנד",

}

TY - CHAP

T1 - CAR 2.0

T2 - The Next Generation of Synthetic Receptor-Based Cellular Therapy for Cancer

AU - Jacoby, Elad

AU - Fry, Terry J.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - The successes of chimeric antigen receptor (CAR) T-cells has revealed many challenges resulting in an explosion of T-cell engineering solutions, most not yet tested in patients. The synthetic nature of the CAR design and almost limitless options that advanced genetic engineering offers pave the way to the next-generation CAR: one that targets multiple antigens with specificity to the tumor, that overcomes immunosuppressive environments in solid tumors or the central nervous system, that has controllable persistence and activation, and that is “off the shelf.” In this chapter, we will cover these challenges and their underlying mechanisms and discuss preclinical and clinical results aimed to tackle them.

AB - The successes of chimeric antigen receptor (CAR) T-cells has revealed many challenges resulting in an explosion of T-cell engineering solutions, most not yet tested in patients. The synthetic nature of the CAR design and almost limitless options that advanced genetic engineering offers pave the way to the next-generation CAR: one that targets multiple antigens with specificity to the tumor, that overcomes immunosuppressive environments in solid tumors or the central nervous system, that has controllable persistence and activation, and that is “off the shelf.” In this chapter, we will cover these challenges and their underlying mechanisms and discuss preclinical and clinical results aimed to tackle them.

KW - Adoptive T-cell therapy

KW - Chimeric antigen receptor

KW - Genetically modified T-cells

KW - T-cell engineering

UR - http://www.scopus.com/inward/record.url?scp=85137590460&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-66181-2.00013-5

DO - 10.1016/B978-0-323-66181-2.00013-5

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:85137590460

SN - 9780323755979

SP - 199

EP - 208

BT - Chimeric Antigen Receptor T-Cell Therapies for Cancer

PB - Elsevier

ER -

CAR 2.0: The Next Generation of Synthetic Receptor-Based Cellular Therapy for Cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this